Cartesian Therapeutics Inc. (RNAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $193.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cartesian Therapeutics Inc. (RNAC) Stock Forecast
Analysts expect Cartesian Therapeutics (RNAC) to earn -$1.23 per share in the fiscal year ending Dec 31, 2026, on revenue of $419140. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.27.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 31.8%.
- Fiscal year ending Dec 31, 2026
- -$1.23
- EPS consensus, revenue $419140
- Fiscal year ending Dec 31, 2027
- -$1.27
- EPS consensus, revenue $285710
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.23 | -$1.23 to -$1.23 | 1 | $419140 | $78000 to $1.00M | 7 |
| Dec 31, 2027 | -$1.27 | -$1.27 to -$1.27 | 1 | $285710 | N/A | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.95 for the quarter ending Dec 31, 2026 to -$0.86 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.95 | -$1.18 to -$0.41 | 9 | $348503 | N/A | 9 |
| Mar 31, 2027 | -$0.86 | -$1.09 to -$0.42 | 6 | $41670 | N/A | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.78.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.23 | -$2.78 | -$2.78 | -$2.78 | -$2.78 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.27 | -$3.81 | -$3.81 | -$3.81 | -$3.81 | N/A |
| Quarter ending Mar 31, 2027 | -$0.86 | -$1.05 | -$1.05 | -$1.05 | -$1.05 | N/A |
Frequently Asked Questions About RNAC
What is the RNAC stock forecast?
Consensus analyst estimates put Cartesian Therapeutics's EPS at -$1.23 for the fiscal year ending Dec 31, 2026, on revenue of $419140. The consensus rating from 7 analysts is Buy.
How do analysts rate RNAC stock?
Of 7 analysts covering Cartesian Therapeutics, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RNAC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.23, with estimates from -$1.23 to -$1.23 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.27, with estimates from -$1.27 to -$1.27 from 1 analyst.
What revenue do analysts expect from Cartesian Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $419140, with estimates from $78000 to $1.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $285710.
How many analysts cover RNAC?
7 analysts rate Cartesian Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
RNAC pages: Overview, Earnings, Forecast, Financials, Competitors